C. Tehlirian

Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

E. Peeva, M. Dowty, A. Banerjee, 2020, Clinical and translational science.

High-dose cyclophosphamide without stem cell rescue in scleroderma

L. Hummers, R. Brodsky, B. White, 2007, Annals of the rheumatic diseases.

Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study

E. Peeva, J. Krueger, S. Garcet, 2021 .

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial.

E. Peeva, S. Forman, Y. Poulin, 2020, The Journal of investigative dermatology.

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.

S. Tarabar, E. Peeva, J. Gale, 2022, Journal of the American Academy of Dermatology.

Rheumatoid arthritis A. clinical and laboratory manifestations

J. Bathon, C. Tehlirian, 2008 .